Literature DB >> 17255519

Severe hypoxia defines heterogeneity and selects highly immature progenitors within clonal erythroleukemia cells.

Serena Giuntoli1, Elisabetta Rovida, Antonella Gozzini, Valentina Barbetti, Maria Grazia Cipolleschi, Massimo Olivotto, Persio Dello Sbarba.   

Abstract

We showed that resistance to severe hypoxia defines hierarchical levels within normal hematopoietic populations and that hypoxia modulates the balance between generation of progenitors and maintenance of hematopoietic stem cells (HSC) in favor of the latter. This study deals with the effects of hypoxia (0.1% oxygen) in vitro on Friend's murine erythroleukemia (MEL) cells, addressing the question of whether a clonal leukemia cell population comprise functionally different cell subsets characterized by different hypoxia resistance. To identify leukemia stem cells (LSC), we used the Culture Repopulating Ability (CRA) assay we developed to quantify in vitro stem cells capable of short-term reconstitution (STR). Hypoxia strongly inhibited the overall growth of MEL cell population, which, despite its clonality, comprised progenitors characterized by markedly different hypoxia-resistance. These included hypoxia-sensitive colony-forming cells and hypoxia-resistant STR-type LSC, capable of repopulating secondary liquid cultures of CRA assays, confirming what was previously shown for normal hematopoiesis. STR-type LSC were found capable not only of surviving in hypoxia but also of being mostly in cycle, in contrast with the fact that almost all hypoxia-surviving cells were growth-arrested and with what we previously found for HSC. However, quiescent LSC were also detected, capable of delayed culture repopulation with the same efficiency as STR-like LSC. The fact that even quiescent LSC, believed to sustain minimal residual disease in vivo, were found within the MEL cells indicates that all main components of leukemia cell populations may be present within clonal cell lines, which are therefore suitable to study the sensitivity of individual components to treatments. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255519     DOI: 10.1634/stemcells.2006-0637

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  28 in total

1.  Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.

Authors:  Serena Giuntoli; Michele Tanturli; Federico Di Gesualdo; Valentina Barbetti; Elisabetta Rovida; Persio Dello Sbarba
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

2.  Very low oxygen concentration (0.1%) reveals two FDCP-Mix cell subpopulations that differ by their cell cycling, differentiation and p27KIP1 expression.

Authors:  A V Guitart; C Debeissat; F Hermitte; A Villacreces; Z Ivanovic; H Boeuf; V Praloran
Journal:  Cell Death Differ       Date:  2010-07-30       Impact factor: 15.828

3.  Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells.

Authors:  E Del Poggetto; M Tanturli; N Ben-Califa; A Gozzini; I Tusa; G Cheloni; I Marzi; M G Cipolleschi; Y Kashman; D Neumann; E Rovida; P Dello Sbarba
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 4.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

Review 5.  Targeting the microenvironment in acute myeloid leukemia.

Authors:  Armin Rashidi; Geoffrey L Uy
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

6.  AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.

Authors:  Donya Moradi Manesh; Jad El-Hoss; Kathryn Evans; Jennifer Richmond; Cara E Toscan; Lauryn S Bracken; Ashlee Hedrick; Rosemary Sutton; Glenn M Marshall; William R Wilson; Raushan T Kurmasheva; Catherine Billups; Peter J Houghton; Malcolm A Smith; Hernan Carol; Richard B Lock
Journal:  Blood       Date:  2015-06-26       Impact factor: 22.113

7.  The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.

Authors:  John M Heddleston; Zhizhong Li; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell Cycle       Date:  2009-10-03       Impact factor: 4.534

8.  Glioblastoma Stem Cells: A Neuropathologist's View.

Authors:  Roger E McLendon; Jeremy N Rich
Journal:  J Oncol       Date:  2010-11-01       Impact factor: 4.375

9.  Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.

Authors:  Giulia Cheloni; Michele Tanturli; Ignazia Tusa; Ngoc Ho DeSouza; Yi Shan; Antonella Gozzini; Fréderic Mazurier; Elisabetta Rovida; Shaoguang Li; Persio Dello Sbarba
Journal:  Blood       Date:  2017-06-02       Impact factor: 22.113

Review 10.  Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence.

Authors:  Armin Rashidi; John F DiPersio
Journal:  Ther Adv Hematol       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.